Cooper M - Search Results

1

Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat.

Gin T, Joon TL, Panagiotopoulos S, Cooper M, Taylor H, Jerums G. Gin T, et al. Among authors: cooper m. Invest Ophthalmol Vis Sci. 1996 Feb;37(2):281-9. Invest Ophthalmol Vis Sci. 1996. PMID: 8603832

2

Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.

Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Soulis-Liparota T, et al. Among authors: cooper m. Diabetes. 1991 Oct;40(10):1328-34. doi: 10.2337/diab.40.10.1328. Diabetes. 1991. PMID: 1834497

3

Effect of glycaemic control on glomerular filtration rate in the streptozotocin diabetic rat.

Jackson B, Franze L, Allen TJ, O'Brien R, Cooper M, Hodsman GP, Jerums G. Jackson B, et al. Among authors: cooper m. Clin Exp Pharmacol Physiol. 1988 Apr;15(4):361-5. doi: 10.1111/j.1440-1681.1988.tb01088.x. Clin Exp Pharmacol Physiol. 1988. PMID: 2978746

4

Microalbuminuria in diabetes.

Jerums G, Cooper M, Gilbert R, O'Brien R, Taft J. Jerums G, et al. Among authors: cooper m. Med J Aust. 1994 Aug 15;161(4):265-8. Med J Aust. 1994. PMID: 8047035

5

Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy.

Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Kelly DJ, et al. J Am Soc Nephrol. 2001 Oct;12(10):2098-2107. doi: 10.1681/ASN.V12102098. J Am Soc Nephrol. 2001. PMID: 11562408

6

A low-sodium diet potentiates the effects of losartan in type 2 diabetes.

Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, Jerums G. Houlihan CA, et al. Diabetes Care. 2002 Apr;25(4):663-71. doi: 10.2337/diacare.25.4.663. Diabetes Care. 2002. PMID: 11919122 Clinical Trial.

7

Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria.

Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM. Forbes JM, et al. Among authors: cooper me. J Hypertens. 2002 May;20(5):985-92. doi: 10.1097/00004872-200205000-00034. J Hypertens. 2002. PMID: 12011660

8

Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.

Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Houlihan CA, et al. Diabetes Care. 2002 Jun;25(6):1072-7. doi: 10.2337/diacare.25.6.1072. Diabetes Care. 2002. PMID: 12032117 Clinical Trial.

9

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Jerums G, Osicka TM. Forbes JM, et al. Among authors: cooper me. Diabetes. 2002 Nov;51(11):3274-82. doi: 10.2337/diabetes.51.11.3274. Diabetes. 2002. PMID: 12401719

10

Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.

Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Davis BJ, et al. Among authors: cooper me. J Hypertens. 2003 Jan;21(1):209-16. doi: 10.1097/00004872-200301000-00031. J Hypertens. 2003. PMID: 12544453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,743 results

Search Page

Filters